 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | GSK2820151 / GSK
Trial completion date, Trial termination, Trial primary completion date, Metastases: Dose Escalation Study of GSK2820151 in Subjects With Advanced or Recurrent Solid Tumors (clinicaltrials.gov) - Oct 8, 2019
P1, N=5, Terminated, Sponsor: GlaxoSmithKline
Trial completion date: May 2019 --> Dec 2018 | Active, not recruiting --> Terminated | Trial primary completion date: May 2019 --> Dec 2018; In 2017, GSK2820151 was terminated due to development of another BET Inhibitor (GSK525762) with a better understanding of the risk benefit profile.
- GSK2820151 / GSK
Enrollment closed, Enrollment change, Metastases: Dose Escalation Study of GSK2820151 in Subjects With Advanced or Recurrent Solid Tumors (clinicaltrials.gov) - Apr 3, 2018
P1, N=5, Active, not recruiting, Sponsor: GlaxoSmithKline
Trial completion date: May 2019 --> Dec 2018 | Active, not recruiting --> Terminated | Trial primary completion date: May 2019 --> Dec 2018; In 2017, GSK2820151 was terminated due to development of another BET Inhibitor (GSK525762) with a better understanding of the risk benefit profile. Recruiting --> Active, not recruiting | N=60 --> 5
- || GSK2820151 / GSK
Trial primary completion date, Metastases: Dose Escalation Study of GSK2820151 in Subjects With Advanced or Recurrent Solid Tumors (clinicaltrials.gov) - Apr 25, 2017
P1, N=60, Recruiting, Sponsor: GlaxoSmithKline
Recruiting --> Active, not recruiting | N=60 --> 5 Trial primary completion date: Mar 2018 --> May 2019
- ||| GSK2820151 / GSK
Enrollment open, Metastases: Dose Escalation Study of GSK2820151 in Subjects With Advanced or Recurrent Solid Tumors (clinicaltrials.gov) - Jan 10, 2017
P1, N=60, Recruiting, Sponsor: GlaxoSmithKline
Trial primary completion date: Mar 2018 --> May 2019 Not yet recruiting --> Recruiting
- || GSK2820151 / GSK
Trial primary completion date, Journal, Metastases: Dose Escalation Study of GSK2820151 in Subjects With Advanced or Recurrent Solid Tumors (clinicaltrials.gov) - Feb 5, 2016
P1, N=60, Not yet recruiting, Sponsor: GlaxoSmithKline
Not yet recruiting --> Recruiting Trial primary completion date: Feb 2017 --> Feb 2018
- ||| GSK2820151 / GSK
New P1 trial, Metastases: Dose Escalation Study of GSK2820151 in Subjects With Advanced or Recurrent Solid Tumors (clinicaltrials.gov) - Dec 15, 2015
P1, N=60, Not yet recruiting, Sponsor: GlaxoSmithKline